TNF-alpha blockade and tuberculosis: better look before you leap

Area of Science:

• Immunology
• Infectious Diseases
• Rheumatology

Background:

• Tumour necrosis factor alpha (TNF)-blocking agents are effective for inflammatory diseases like rheumatoid arthritis and Crohn's disease.
• These agents increase the risk of active tuberculosis in patients with latent Mycobacterium tuberculosis infection.
• Unusual and severe clinical presentations of infections are noted in patients on TNF-blocking agents.

Purpose of the Study:

• To review the risk of intracellular pathogen infection, particularly tuberculosis, in patients treated with TNF-blocking agents.
• To discuss the role of TNF in tuberculosis pathogenesis.
• To outline the risk profile and preventive strategies for tuberculosis during TNF blockade.

Main Methods:

• Review of current data on infection risk with TNF-blocking agents.
• Discussion of TNF's role in tuberculosis pathogenesis.
• Presentation of a provisional clinical flowchart for risk minimization.

Main Results:

• TNF-blocking agents are associated with an increased risk of active tuberculosis.
• TNF plays a significant role in the pathogenesis of tuberculosis.
• A provisional flowchart is provided to guide risk assessment and management.

Conclusions:

• Healthcare providers must be aware of the increased tuberculosis risk associated with TNF-blocking agents.
• Preventive measures and careful monitoring are essential for patients on these therapies.
• A structured approach can help minimize the risk of tuberculosis during TNF blockade.